MARSHALL WACE ASIA Ltd grew its position in Humana Inc (NYSE:HUM) by 0.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 223,379 shares of the insurance provider’s stock after purchasing an additional 1,013 shares during the quarter. Humana makes up 2.6% of MARSHALL WACE ASIA Ltd’s investment portfolio, making the stock its 15th largest position. MARSHALL WACE ASIA Ltd’s holdings in Humana were worth $75,618,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in HUM. Janney Montgomery Scott LLC raised its holdings in shares of Humana by 4.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,791 shares of the insurance provider’s stock valued at $1,426,000 after purchasing an additional 213 shares in the last quarter. Commonwealth Equity Services LLC grew its position in shares of Humana by 18.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 8,053 shares of the insurance provider’s stock valued at $2,397,000 after buying an additional 1,269 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Humana by 2,984.6% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 401 shares of the insurance provider’s stock valued at $119,000 after buying an additional 388 shares during the last quarter. Smith Asset Management Group LP grew its position in shares of Humana by 4.4% in the 2nd quarter. Smith Asset Management Group LP now owns 109,050 shares of the insurance provider’s stock valued at $32,457,000 after buying an additional 4,590 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Humana by 425.8% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 24,975 shares of the insurance provider’s stock valued at $7,433,000 after buying an additional 20,225 shares during the last quarter. Institutional investors and hedge funds own 92.90% of the company’s stock.
A number of research analysts recently commented on HUM shares. Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $377.00 target price on the stock in a research report on Thursday, October 4th. Argus increased their target price on shares of Humana to $375.00 and gave the company a “buy” rating in a research report on Tuesday, September 4th. Piper Jaffray Companies increased their target price on shares of Humana from $355.00 to $380.00 and gave the company an “overweight” rating in a research report on Friday, August 24th. Barclays started coverage on shares of Humana in a research report on Thursday, September 13th. They issued an “overweight” rating and a $370.00 target price on the stock. Finally, Royal Bank of Canada increased their target price on shares of Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research report on Thursday, November 8th. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $352.10.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.29 by $0.29. Humana had a net margin of 2.70% and a return on equity of 19.10%. The company had revenue of $14.21 billion for the quarter, compared to the consensus estimate of $13.97 billion. During the same period last year, the firm posted $3.39 EPS. As a group, equities analysts expect that Humana Inc will post 14.43 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 0.63%. The ex-dividend date is Friday, December 28th. Humana’s payout ratio is currently 11.96%.
In other news, insider Roy A. Beveridge sold 4,622 shares of Humana stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the sale, the insider now owns 10,621 shares of the company’s stock, valued at $3,622,398.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce D. Broussard sold 18,000 shares of Humana stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the sale, the chief executive officer now directly owns 71,085 shares in the company, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. Company insiders own 0.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.wkrb13.com/2018/12/07/marshall-wace-asia-ltd-has-75-62-million-stake-in-humana-inc-hum.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Featured Story: What is Liquidity?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.